Related Experiment Video
Updated: Mar 12, 2026
Isolation and Flow Cytometric Assessment of Neuroimmune Interactions in a Mini-Stroke Murine Model
Published on: June 20, 2025
Minocycline Suppresses NLRP3 Inflammasome Activation in Experimental Ischemic Stroke
Yunnan Lu1, Guodong Xiao, Weifeng Luo
1Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Objective:
Minocycline, a tetracycline antibiotic, has shown anti-inflammatory effects in cerebral ischemia and neurodegenerative disease; however, the molecular mechanisms underlying this effect have not been clearly identified. Since NLRP3 inflammasome activation controls the maturation and release of proinflammatory cytokines, especially interleukin-1β (IL-1β) and IL-18 in ischemia stroke, we suppose that minocycline may be involved in the regulation of NLRP3 inflammasome activation.
Methods:
We investigated the effects of minocycline on NLRP3 inflammasome activation using the transient middle cerebral artery occlusion (tMCAO) mouse model and an in vitro oxygen-glucose deprivation/reoxygenation injury model in BV2 microglial cells.
Results:
We found that minocycline administrated 1 h after reperfusion can improve neurological disorder, reduce infarct volume, and alleviate cerebral edema. Meanwhile, we showed that minocycline prevented the activation of microglias and attenuated NLRP3 inflammasome signaling after tMCAO injury. Furthermore, we found that the pretreatment of minocycline significantly inhibited signal 1 and signal 2 of NLRP3 inflammasome activation in BV2 cells.
Conclusion:
We demonstrated that minocycline can ameliorate ischemia-induced brain damage via inhibiting NLRP3 inflammasome activation.
Insights
Minocycline, an antibiotic, reduces brain damage after stroke by inhibiting the NLRP3 inflammasome pathway. This anti-inflammatory action improves neurological function and reduces lesion size in ischemic stroke models.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Minocycline exhibits anti-inflammatory properties relevant to cerebral ischemia and neurodegenerative diseases.
- The precise molecular mechanisms of minocycline's neuroprotective effects remain unclear.
- NLRP3 inflammasome activation is critical in releasing pro-inflammatory cytokines during ischemic stroke.
Purpose of the Study:
- To investigate the effect of minocycline on NLRP3 inflammasome activation in the context of ischemic stroke.
- To elucidate the role of minocycline in regulating NLRP3 inflammasome signaling pathways.
Main Methods:
- Utilized a transient middle cerebral artery occlusion (tMCAO) mouse model to simulate ischemic stroke.
- Employed an in vitro oxygen-glucose deprivation/reoxygenation model using BV2 microglial cells.
- Assessed neurological deficits, infarct volume, cerebral edema, and microglial activation.
Main Results:
- Minocycline administration post-reperfusion improved neurological function, reduced infarct volume, and alleviated cerebral edema.
- Minocycline inhibited microglial activation and attenuated NLRP3 inflammasome signaling in the tMCAO model.
- Pretreatment with minocycline significantly suppressed key signaling pathways of NLRP3 inflammasome activation in BV2 cells.
Conclusions:
- Minocycline ameliorates ischemia-induced brain damage by inhibiting NLRP3 inflammasome activation.
- Minocycline demonstrates therapeutic potential for treating ischemic stroke through its anti-inflammatory and NLRP3-inhibiting mechanisms.
